Silencing of lncRNA KLF3‐AS1 represses cell growth in osteosarcoma via miR‐338‐3p/MEF2C axis

Abstract

Osteosarcoma (OS) is a severe bone malignancy mainly occurring among adolescents under twenty-five years old. 1 It is generally characterized by bone pain and dysfunction. 2 Although various options for OS treatment, such as aggressive surgery and chemoradiotherapy, have improved the 5-year survival rate to approximately 60%, some OS patients still suffered from high rate of recurrence. 3 Therefore, comprehending the pathogenesis of OS is imperative to formulate efficacious therapeutic procedures.Long non-coding RNA (lncRNA) are 200 nt in length and can regulate post-transcription. 4 LncRNAs have been reported to have

Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis

“…The lncRNAs that were more frequently downregulated in different cohorts, but that had not been previously related to EOC diagnosis, were PGM5-AS1 , ENSG00000267058 , EPM2A-DT , NR2F1-AS1 , KLF3-AS1 , GLIDR , ERVK13-3 , and CLN8-AS1 , as shown in Figure 2 b. PGM5-AS1 ( ENSG00000224958 ) is downregulated in both EOC patients and EOC cell lines; it is also downregulated and negatively correlated with oxaliplatin resistance in colorectal cancer [ 66 ] but, on the other hand, it is upregulated and sponges miR-140-5p to prevent FBN1 mRNA degradation in osteosarcoma [ 67 ]. KLF3-AS1 is downregulated in esophageal squamous cell carcinoma stem cells, promoting cell migration and invasion by being unable to sponge miR-185-5p, which induces KLF3 mRNA degradation, thereby preventing transcriptional repression of SOX2 and OCT4 by KLF3 [ 68 ], and acts as a competing endogenous tumor suppressor RNA in gastric cancer [ 69 ] and osteosarcoma [ 70 ]. Conversely, several lncRNAs that are downregulated in EOC are upregulated and stimulate cancer progression in other tissues.…”